Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
Philipp Jansen(German Cancer Research Center), Klaus Griewank(Düsseldorf University Hospital), Jochen Utikal(German Cancer Research Center), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Inga Möller(Düsseldorf University Hospital), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Wolfgang Galetzka(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Fabian Standl(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Georg Lodde(Essen University Hospital), Annette Paschen(University of Duisburg-Essen), Elisabeth Livingstone(German Cancer Research Center), Antje Sucker(German Cancer Research Center), Selma Ugurel(Klinikum Bielefeld), Lisa Zimmer(The University of Sydney), Anne Zaremba(National Center for Tumor Diseases), Andreas Stang(Boston University), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Jennifer Landsberg(University of Bonn), Jens Ulrich, Eva Hadaschik(West German Heart and Vascular Center Essen), Jan-Malte Placke(Düsseldorf University Hospital), Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 4
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k